Polyethylene glycol 3350
/ Polyethylene Glycol 3350 / Potassium / / /, Clenz-lyte, Golytely, Halflytely, Miralax, Moviprep, Nulytely, Ocl, Plenvu, Polyethylene Glycol, Polyethylene Glycol 3350 / Potassium / Bicarbonate /, Polyethylene Glycol 3350 / Potassium / Bicarbonate / /, Suclear, Suflave (polyethylene glycol 3350) is a small molecule pharmaceutical. Polyethylene glycol 3350 was first approved as Golytely on 1984-07-13. It is used to treat constipation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Combinations
Golytely, Moviprep, Nulytely, Peg, potassium chloride, bicarbonate,, Peg, sulfate, chloride, potassium chloride, ascorbate ascorbic acid, Plenvu, Polyethylene glycol 3350 electrolytes, Suflave (discontinued: Clenz-lyte, Co-lav, Colyte with flavor packs, Go-evac, Golytely, Halflytely, Lax-lyte with flavor packs, Ocl, Peg 3350 electrolytes, Peg, potassium chloride, bicarbonate,, Peg-lyte, Polyethylene glycol 3350 electrolytes, Suclear, Trilyte)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bisacodyl
+
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALFLYTELY | Braintree Laboratories | N-021551 DISCN | 2010-07-16 | 1 products, RLD |
Hide discontinued
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium sulfate anhydrous
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GOLYTELY | Braintree Laboratories | N-019011 RX | 1984-07-13 | 1 products, RLD, RS |
Show 5 discontinued
Ascorbic acid
+
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium ascorbate
+
Sodium chloride
+
Sodium sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PLENVU | Salix Pharmaceuticals | N-209381 RX | 2018-05-04 | 1 products, RLD, RS |
| MOVIPREP | Salix Pharmaceuticals | N-021881 RX | 2006-08-02 | 1 products, RLD, RS |
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NULYTELY | Braintree Laboratories | N-019797 RX | 1991-04-22 | 1 products, RLD, RS |
| NULYTELY-FLAVORED | Braintree Laboratories | N-019797 RX | 1994-11-18 | 1 products, RLD, RS |
Magnesium sulfate
+
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium chloride
+
Sodium sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUFLAVE | Braintree Laboratories | N-215344 RX | 2023-06-15 | 1 products, RLD, RS |
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium sulfate
Magnesium sulfate
+
Polyethylene glycol 3350
+
Potassium chloride
+
Potassium sulfate
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUCLEAR | Braintree Laboratories | N-203595 DISCN | 2013-01-18 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| advance relief eye drops | OTC monograph final | 2019-12-06 |
| advanced relief | OTC monograph final | 2023-02-17 |
| archies dry eye relief | C200263 | 2023-11-15 |
| artificial tears | OTC monograph final | 2019-10-28 |
| assured advanced relief eye | OTC monograph final | 2013-02-28 |
| avenova lubricant eye drops high performance | C200263 | 2023-12-23 |
| basic care clearlax | ANDA | 2023-01-24 |
| basic care eye | OTC monograph final | 2023-02-15 |
| berkley and jensen clearlax | ANDA | 2023-05-12 |
| best choice eye drops advanced relief | C200263 | 2023-12-23 |
Show 237 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MAGNESIUM SULFATE / POLYETHYLENE GLYCOL 3350 / POTASSIUM CHLORIDE / SODIUM CHLORIDE / SODIUM SULFATE, SUFLAVE, BRAINTREE LABS | |||
| 2026-06-15 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ascorbic Acid / Polyethylene Glycol 3350 / Potassium Chloride / Sodium Ascorbate / Sodium Chloride / Sodium Sulfate, Plenvu, Salix | |||
| 8999313 | 2033-09-10 | DP | |
| 9326969 | 2033-09-10 | U-2310 | |
| 9707297 | 2033-09-10 | DP | |
| 10016504 | 2033-09-10 | DP | |
| 10918723 | 2033-09-10 | U-2310 | |
| 9592252 | 2032-08-11 | DP | U-2310 |
| 10646512 | 2032-03-25 | DP | |
| 10780112 | 2032-03-09 | DP | |
| 10792306 | 2032-03-09 | DP | U-2310 |
| 11529368 | 2032-03-09 | DP | U-2310 |
| Ascorbic Acid / Polyethylene Glycol 3350 / Potassium Chloride / Sodium Ascorbate / Sodium Chloride / Sodium Sulfate, Moviprep, Salix Pharms | |||
| 7169381 | 2024-09-01 | DS, DP | |
| 7658914 | 2024-09-01 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
1358 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 57 | 48 | 50 | 57 | 99 | 297 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 7 | 27 | 39 | 26 | 47 | 139 |
| Hepatitis c | D006526 | — | B19.2 | 10 | 22 | 36 | 27 | 40 | 130 |
| Hiv | D006678 | — | — | 11 | 16 | 10 | 25 | 55 | 116 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 5 | 19 | 31 | 22 | 33 | 107 |
| Infections | D007239 | EFO_0000544 | — | 13 | 17 | 20 | 16 | 40 | 103 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 18 | 12 | 17 | 13 | 41 | 97 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 11 | 45 | 14 | 13 | 83 |
| Colonoscopy | D003113 | — | — | — | 4 | 19 | 22 | 35 | 79 |
| Constipation | D003248 | HP_0002019 | K59.0 | 3 | 10 | 11 | 35 | 17 | 74 |
Show 151 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 9 | 21 | 21 | — | 2 | 47 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 9 | 18 | 20 | — | 2 | 44 |
| Lymphoid leukemia | D007945 | — | C91 | 9 | 18 | 19 | — | 2 | 43 |
| Covid-19 | D000086382 | — | — | 2 | 7 | 9 | — | 3 | 20 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 5 | — | 5 | 11 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 3 | 5 | — | — | 9 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 1 | 1 | — | 5 | 9 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | 1 | — | 6 | 9 |
| Hepacivirus | D016174 | — | — | 1 | 1 | 5 | — | 1 | 8 |
| Recurrence | D012008 | — | — | 2 | 4 | 1 | — | 1 | 7 |
Show 73 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 10 | 11 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 4 | — | — | 2 | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 4 | — | — | 1 | 6 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 3 | — | — | 2 | 5 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | 4 | — | — | 1 | 5 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | 1 | 4 | — | — | 1 | 5 |
| Adenocarcinoma | D000230 | — | — | 3 | 2 | — | — | 2 | 5 |
| Sclerosis | D012598 | — | — | 2 | 2 | — | — | 1 | 4 |
| Postoperative pain | D010149 | — | G89.18 | — | 2 | — | — | 2 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | 1 | 3 |
Show 79 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 4 | — | — | — | 2 | 6 |
| Pharmacokinetics | D010599 | — | — | 4 | — | — | — | — | 4 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | 1 | 2 |
| Diverticulitis | D004238 | EFO_1001460 | K57 | 1 | — | — | — | 1 | 2 |
| Warts | D014860 | — | B07 | 1 | — | — | — | 1 | 2 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | 2 | — | — | — | — | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | — | — | — | — | 1 |
| Reticulocyte count | D017701 | — | — | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | — | — | 4 | 4 |
| Disease progression | D018450 | — | — | — | — | — | — | 4 | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 4 | 4 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 3 | 3 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | — | — | — | 3 | 3 |
| Fecal incontinence | D005242 | — | R15 | — | — | — | — | 3 | 3 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 3 | 3 |
| Risk-taking | D012309 | — | — | — | — | — | — | 2 | 2 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | — | 2 | 2 |
| Keratoconjunctivitis | D007637 | — | H16.2 | — | — | — | — | 2 | 2 |
Show 107 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Polyethylene glycol 3350 |
| INN | macrogol |
| Description | Macrogol, also known as polyethylene glycol (PEG), is used as a medication to treat constipation in children and adults. It is taken by mouth. Benefits usually occur within three days. Generally it is only recommended for up to two weeks. It is also used as an excipient. It is also used to clear the bowels (known as "bowel prep") before a colonoscopy, when the onset of the laxative effect is more rapid, typically within an hour.
|
| Classification | Small molecule |
| Drug class | Osmotic laxative |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201479 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09287 |
| UNII ID | 3WJQ0SDW1A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 29,492 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mircera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
59,150 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use